Zydus Lifesciences exceeded expectations in the June quarter with a 6% revenue growth to ₹6,573 crore and a net profit of ₹1,466 crore. The company looks to expand its biosimilars portfolio in the US following a $125 million acquisition, aiming for new growth avenues.